This HTML5 document contains 38 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n14http://linked.opendata.cz/resource/drugbank/drug/DB05088/identifier/chemspider/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n13http://linked.opendata.cz/resource/drugbank/drug/DB05088/identifier/chebi/
n7http://linked.opendata.cz/resource/drugbank/drug/DB05088/identifier/wikipedia/
n11http://bio2rdf.org/drugbank:
n9http://linked.opendata.cz/resource/drugbank/drug/DB05088/identifier/pubchem-compound/
admshttp://www.w3.org/ns/adms#
n6http://linked.opendata.cz/resource/drugbank/drug/DB05088/identifier/pubchem-substance/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n8http://linked.opendata.cz/resource/drugbank/drug/DB05088/identifier/drugbank/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB05088
rdf:type
n3:Drug
n3:description
Tetrathiomolybdate is an oral, small-molecule, anticopper agent that is highly specific for lowering the levels of free copper in serum. COPREXA has completed pivotal clinical trials for the treatment of neurologic Wilson's disease. It is also developed for fibrotic disorders based upon the rationale that the fibrotic disease process is dependent upon the availability of free copper in the body.
n3:group
investigational
n3:indication
Investigated for use/treatment in liver disease and pulmonary fibrosis.
owl:sameAs
n11:DB05088
dcterms:title
Tetrathiomolybdate
adms:identifier
n6:7807218 n7:Tetrathiomolybdate n8:DB05088 n9:5245480 n13:30703 n14:4413909
n3:mechanismOfAction
Tetrathiomolybdate has demonstrated the ability to inhibit fibrosis in a number of well established animal models through the sequestration of available copper and inhibition of key fibrotric cytokines, including secreted protein acid rich in cysteine (SPARC), NFkappaB, TGF-beta, FGF-2, IL-1, IL-6, IL-8, and connective tissue growth factor (CTGF).
n3:synonym
ATN-224
n3:IUPAC-Name
n4:271B6379-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B637F-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B637E-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B637B-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B637C-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B637D-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B6378-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B6385-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B6386-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B6380-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B6381-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B6383-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B6382-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B6384-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
16330-92-0
n3:category
n3:Bioavailability
n4:271B6389-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B638B-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B638C-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B638D-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B6388-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B6387-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B638A-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B637A-363D-11E5-9242-09173F13E4C5